More importantly, as a drug currently in clinical use, nilotinib can play a better antitumor effect by simultaneously targeting tumor cells and immune microenvironment by reprogramming the intracellular cholesterol metabolism of tumor cells and enhancing CD8+ T cells and neutrophils. Here, CD8A is linked to neoplasm.